- Home
- ZLAB vs FHI Comparison
ZLAB vs FHI Comparison
Compare ZLAB & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- FHI
- Stock Information
- Founded
- ZLAB 2013
- FHI 1955
- Country
- ZLAB China
- FHI United States
- Employees
- ZLAB N/A
- FHI N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- FHI Investment Managers
- Sector
- ZLAB Health Care
- FHI Finance
- Exchange
- ZLAB Nasdaq
- FHI Nasdaq
- Market Cap
- ZLAB 3.6B
- FHI 3.4B
- IPO Year
- ZLAB 2017
- FHI N/A
- Fundamental
- Price
- ZLAB $34.55
- FHI $42.46
- Analyst Decision
- ZLAB Buy
- FHI Hold
- Analyst Count
- ZLAB 4
- FHI 6
- Target Price
- ZLAB $47.37
- FHI $42.33
- AVG Volume (30 Days)
- ZLAB 1.0M
- FHI 884.0K
- Earning Date
- ZLAB 08-05-2025
- FHI 07-24-2025
- Dividend Yield
- ZLAB N/A
- FHI 3.21%
- EPS Growth
- ZLAB N/A
- FHI 2.09
- EPS
- ZLAB N/A
- FHI 3.58
- Revenue
- ZLAB $418,326,000.00
- FHI $1,659,262,000.00
- Revenue This Year
- ZLAB $44.07
- FHI $5.57
- Revenue Next Year
- ZLAB $49.13
- FHI $3.48
- P/E Ratio
- ZLAB N/A
- FHI $11.82
- Revenue Growth
- ZLAB 43.72
- FHI 2.19
- 52 Week Low
- ZLAB $16.01
- FHI $31.59
- 52 Week High
- ZLAB $44.34
- FHI $43.92
- Technical
- Relative Strength Index (RSI)
- ZLAB 49.05
- FHI 53.81
- Support Level
- ZLAB $36.36
- FHI $41.71
- Resistance Level
- ZLAB $44.34
- FHI $42.92
- Average True Range (ATR)
- ZLAB 1.45
- FHI 0.67
- MACD
- ZLAB -0.16
- FHI -0.09
- Stochastic Oscillator
- ZLAB 39.20
- FHI 66.42
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).